CYP1B1 G199T Polymorphism Affects Prognosis of NSCLC Patients with the Potential to Be an Indicator and Target for Precise Drug Intervention

Table 3

Cox’s proportional hazard regression model for univariate analysis.

Variables	Disease-free survival				Overall survival
		Exp (B)/HR	95% CI			Exp (B)/HR	95% CI
			Lower	Upper			Lower	Upper
Gender (male)	0.119	1.425	0.913	2.224	0.165	1.377	0.876	2.162
Age (≥66)	0.710	0.924	0.608	1.404	0.648	0.906	0.593	1.383
Smoking (never)	0.807	1.054	0.690	1.610	0.777	1.064	0.694	1.630
Pathological type
AD	0.017	1.000			0.019	1.000
SQ	0.164	0.707	0.433	1.153	0.266	0.754	0.459	1.240
LA	0.040	1.877	1.028	3.428	0.024	2.005	1.096	3.669
Others	0.209	0.519	0.187	1.444	0.269	0.561	0.202	1.564
Differentiation
Poor	0.012	1.000			0.004	1.000
Moderate	0.119	0.701	0.449	1.096	0.124	0.704	0.451	1.101
Well	0.004	0.298	0.131	0.675	0.001	0.212	0.082	0.543
T stage
T1	0.001	1.000			0.001	1.000
T2	0.002	3.265	1.571	6.788	0.000	0.187	0.083	0.422
T3	0.008	2.773	1.298	5.924	0.076	0.590	0.329	1.057
T4	0.000	5.196	2.305	11.713	0.082	0.580	0.315	1.071
N stage
N0	0.000	1.000			0.000	1.000
N1	0.017	2.073	1.140	3.768	0.004	2.447	1.331	4.499
N2	0.000	3.197	1.938	5.276	0.000	3.589	2.146	6.002
N3	0.002	7.186	2.117	24.396	0.001	7.839	2.318	26.516
M stage (M1)	0.000	2.538	1.526	4.221	0.001	2.484	1.478	4.174
Clinical stage
I	0.000	1.000			0.000	1.000
II	0.003	3.513	1.538	8.025	0.001	3.923	1.693	9.092
IIIa	0.001	2.844	1.500	5.394	0.001	3.194	1.653	6.173
IIIb	0.000	5.266	2.348	11.810	0.000	5.608	2.466	12.751
V	0.000	5.896	2.899	11.989	0.000	6.246	3.002	12.997
G199T (mutant)	0.030	1.592	1.047	2.420	0.022	1.640	1.074	2.505
C432G (mutant)	0.700	0.905	0.545	1.504	0.603	0.874	0.525	1.454